Dr. Minying Cai is currently a research professor in the Department of Chemistry and Biochemistry at the University of Arizona. She has been working in the Chemistry & Biochemistry department for more than 20 years and has more than 100 publications and numerous patents in the area of novel drug discovery for obesity, diabetes, cancer, pain and neuro-disorder diseases. Dr. Cai received the Ph.D. at the University of Arizona in Biochemistry and Molecular Biophysics. Before that, she was a well developed researcher in Shanghai Institute of Materia Medica; Shanghai Research Center of Biotechnology in Chinese Academy of Sciences.
Melanoma is the most deadly form of skin cancer in the United States. Recent breakthroughs of BRAF-V600E inhibitors and PD-1 inhibitors have successfully prolonged the median overall survival for malignant melanoma patients. Nevertheless, tumor cells eventually relapse and become resistant to these treatments. We are developing new technologies and new therapeutics to block the cancer resistance. Our lately designed molecules can specifically prevent melanoma. In collaboration with other investigators worldwide, we aim to identify and develop molecule modulators of membrane proteins and signaling proteins for the therapeutic treatment of melanoma without resistance.